DNAnexus Expands Executive Team With Chief Technology Officer

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--DNAnexus, the leader in cloud-based genome informatics and data management, today announced that Mr. Balaji Venkateswaran has been named Chief Technology Officer of the growing bioinformatics company.

"I'm excited to be part of such a dynamic company which has been built on the security principles required to allow customers to conduct their DNA-based research on a global scale."

Venkateswaran brings more than twenty years of experience building highly-scalable global software products, many with a focus on security. Most recently he was Co-Founder and Vice President of Engineering at Layer8 Security, where he conceived and built an innovative cloud security platform. Prior to Layer8, he held various management and executive positions at Symantec, GuardianEdge Technologies (acquired by Symantec), Elemental Cyber Security, and Evolve Software (now part of Oracle). Venkateswaran has an MS in Computer Engineering from the University of South Carolina.

"Balaji has an impressive background of leading and growing teams that build world-class technology," said Richard Daly, CEO of DNAnexus. "His experience in security will benefit our customers as we continue to grow the global network that helps them securely and compliantly analyze, manage and share genomic data in the cloud."

"The intersection of genomic medicine and the cloud is disrupting medical discovery as we know it," added Mr. Venkateswaran. "I'm excited to be part of such a dynamic company which has been built on the security principles required to allow customers to conduct their DNA-based research on a global scale."

About DNAnexus

DNAnexus combines expertise in cloud computing and bioinformatics to create the global network for genomic medicine. DNAnexus provides security, scalability and collaboration for enterprises and organizations that are pursuing genomic-based approaches to health in order to accelerate medical discovery. DNAnexus is supporting customers around the world that are tackling some of the most challenging and exciting opportunities in human health. For more information, please visit: https://dnanexus.com and follow us at @DNAnexus.

Contacts

Element Public Relations
Tim Smith, 415-350-3019
[email protected]

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

While the biotech IPO market booms, it can look like going public is easy. But the right strategy, syndicate and aftermarket are still important.

Gene therapy pioneer Jim Wilson and the University of Pennsylvania are teaming up with Regeneron to help deliver its COVID antibody intransally.

Forty percent of PK deficiency patients on mitapivat had hemoglobalin responses, compared to 0% in the placebo group.